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End-stage renal disease (ESRD) is a growing public health
concern and non-adherence to treatment has been
associated with poorer health outcomes in this population.
Depression, likely to be the most common psychopathology
in such patients, is associated with increased morbidity and
mortality. We compared psychological measures and
self-reported medication adherence of 94 kidney transplant
recipients to those of 65 patients receiving hemodialysis in a
major medical center in Brooklyn, New York. Compared to
the transplant group, the hemodialysis cohort was
significantly more depressed as determined by the Beck
Depression Inventory score. They also had a significantly
lower adherence to medication as reported on the
Medication Therapy Adherence Scale. Using hierarchical
multiple regression analysis, the variance in depression was
the only statistically significant predictor of medication
adherence beyond gender and mode of treatment,
accounting for an additional 12% of the variance. Our study
strongly suggests that a depressive affect is an important
contributor to low medication adherence in patients with
ESRD on hemodialysis or kidney transplant recipients.
Kidney International (2009) 75, 1223–1229; doi:10.1038/ki.2009.51;
published online 25 February 2009
KEYWORDS: adherence; depression; hemodialysis; transplantation
Lack of adherence to prescribed end-stage renal disease
(ESRD) treatments is a public health issue, as it is a major
contributor to poor outcome in this increasingly prevalent
medical condition. The two most common methods of
treatment for ESRD, hemodialysis (HD) and kidney trans-
plantation (TX), both require strict adherence to a medical
regimen.1 In 2004, non-adherence to treatment in kidney
transplantation alone cost the United States approximately
$100 million annually.2 In addition to the economic burden,
non-adherence to immunosuppressive medication in renal
transplantation is a primary cause of kidney rejection3 with
one meta-analysis finding that non-adherent transplant
patients are seven times more likely to have graft failure
than those who were adherent.4 Medication adherence,
dietary and fluid adherence, and treatment attendance are
all essential components of the dialysis prescription, and
non-adherence has been associated with increased mortality.5
Transplant centers consider adherence to HD treatment as an
important factor when evaluating their patients for kidney
transplantation.6 There is, however, a lack of detailed analysis
of factors associated with non-adherence in HD populations.
Some characteristics that have been suggested to be
important for adherence behavior in kidney transplant
patients include fewer medical complications, age, cardio-
vascular risk, HIV infection, illicit drug use, and presence of
severe mental psychopathology.6–9
Several studies10–13 have found older HD patients as well
as older transplant patients14 to be more adherent. Kimmel
et al.15 found women to be more adherent with amount of
time spent on HD as well as attendance at treatment. One
multicenter study12 of 916 HD patients found males receiving
HD to be less adherent with diet and fluid intake. Jindal
et al.16 concluded that women transplant patients were less
adherent regarding their medication compared with men.
Ethnicity has also been associated with adherence, with
blacks showing less adherence.13,16,17
Psychological variables have also emerged as important
predictors of adherence. Depression has been associated with
increased morbidity and mortality in ESRD18–20 and is
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considered the most common psychopathology among ESRD
patients,21,22 with the prevalence of depressive disorders
ranging from approximately 20 to 30%.23 Depressed indivi-
duals across various medical conditions were 3 times more
likely to be non-adherent to medical recommendations when
compared with non-depressed individuals.24 In other illnesses,
depression has been identified as a modifiable risk factor for
non-adherence, and interventions to promote adherence have
been developed that address mood state.25–27
Locus of control (LOC) is another psychological variable
that is associated with well-being.28 LOC describes an
individual’s belief regarding where the control over his or
her health lies. This construct can be understood as having
three dimensions, including internal (i.e., the individual is
responsible for his or her health), powerful other (i.e., control
over outcome lies in the hands of the physician or God), and
chance (i.e., luck/random effects are the most powerful
predictors of health outcome). LOC has been examined in
ESRD samples.29–31 In a study of kidney transplant patients,
‘internal’ and ‘chance’ LOC were associated with worse
adherence, whereas ‘powerful other’ LOC was associated with
better adherence to the medication regimen.31 Another study
found the reverse relationship, showing that ESRD patients
treated with HD and who had an ‘internal’ LOC reported
higher levels of compliance, although this relationship was
true only for females but not for males.32 This study seeks to
examine the utility of this construct in predicting adherence
in an ESRD sample of patients receiving HD and recipients of
kidney transplantation.
In our previous analysis of depression, LOC, and
adherence in a kidney transplant population, we found that
individuals who had undergone transplantation and had
perceived control over their outcome had decreased levels of
depression when compared with patients who attributed
their health outcome to chance.33 The belief that health was
controlled by ‘chance’ significantly correlated with increased
depressive affect. In addition, higher levels of depression
correlated with missing more medication doses. The aim of
this study is to expand our understanding of this cohort by
comparing it with a broadly similar cohort of HD patients. It
was hypothesized that depressive affect would be a significant
predictor of self-reported medication adherence in both
ESRD samples. In addition, it was hypothesized that the HD
cohort would report greater depressive affect compared with
patients with a functioning kidney transplant.
RESULTS
Ninety-four recipients of functioning kidney transplants and 65
HD patients completed the self-report standardized instru-
ments for a total of 159 participants. Fifty-eight percent of the
total sample was born in the United States and 46% were
female (Table 1). The average age of the sample was 46.9±12.9
years. Twenty-seven percent reported being currently em-
ployed, and the average amount of education was 12.2±2.9
years. Eighty-one percent of the entire sample identified
themselves as black, 10% as Hispanic, 4% as white, and 5%
as multiethnic/other. The overall sample reported 1.3±2.4
hospitalizations within the last year.
For the overall sample, the average Beck Depression
Inventory (BDI) score was 8.9±9.5 (non-depressed) and the
mean score on the Medication Therapy Adherence Scale
(ITAS-M) was 10.4±2.7 (nearly perfect adherence). On the
LOC, the average scores for ‘internal influences,’ ‘powerful
other,’ and ‘chance’ were 24.7±8.1, 22.9±5.8, and 17.3±6.0,
respectively (Table 1).
Subsample analyses
The sample was divided between participants receiving HD
and those with a functioning kidney transplant. Transplant
patients were younger (t (152)¼ 3.38, P¼ 0.001) and had
fewer hospitalizations compared with HD patients (t (148)¼
3.52, P¼ 0.001) (Table 1). A greater proportion of HD
patients identified themselves as black (w2¼ 8.51, P¼ 0.004),
but the groups did not differ in gender (w2¼ 3.05, P¼ 0.10),
education (t (146)¼0.49, P¼ 0.62), or employment status
(w2¼ 2.41), P¼ 0.15).
As hypothesized, the HD cohort was significantly more
depressed (12.6±9.8) than those with an active transplant
(6.2±8.3) (t¼ 4.35, Po0.001). In addition, HD patients
reported less medication adherence (9.6±3.0) than those in
Table 1 | Demographic and psychological variables
(mean±s.d. or percent)
Variable
Total sample
(n=159)
Transplant
(n=94)
Hemodialysis
(n=65)
Age (years) 46.9±12.9 44.1±12.2** 51.1±13.0**
Gender
Male 54% 60% 46%
Female 46% 40% 54%
Working 27% 32% 21%
Education (years) 12.2±2.9 12.3±2.8 12.1±3.0
Hospitalizations 1.3±2.4 0.7±1.2** 2.1±3.3**
Treatment length, in that
modality (months)
42.0±57.7 51.0±46.5
Ethnicity (self-report)
African/Caribbean-
American
81% 72%** 93%**
Hispanic 10% 17% 2%
Caucasian 4% 6% 2%
Multi-ethnic/other 5% 5% 3%
US born 58% 62% 52%
Beck Depression Inventory 8.9±9.5 6.2±8.3** 12.6±9.8**
Medication Therapy Adherence Scale
Adherence 10.4±2.7 11.0±2.4** 9.6±3.0**
Perfect Adherence 51% 60%* 39%*
Nearly Perfect Adherence 30% 34% 25%
Less Than Perfect Adherence 19% 6%** 37%**
Mental Health Locus of Control Scales
Internal 24.7±8.1 25.1±9.6 24.0±5.3
Powerful Other 22.9±5.8 22.9±6.0 23.0±5.4
Chance 17.3±6.0 16.4±6.0* 18.7±5.8*
*Po0.05, **Po0.01 (transplant vs hemodialysis).
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the transplant group (11.0±2.4), (t¼3.19, P¼ 0.002).
Furthermore, those in the HD group reported more of a
‘chance’ LOC than those in the transplant group (t¼ 2.26,
P¼ 0.025). There were no significant differences between any
of the demographic or psychological variables when the
entire sample was divided by race (black, n¼ 107 compared
with other, n¼ 27, P40.05, all cases) or gender (female,
n¼ 69 compared with male, n¼ 85, P40.05, all cases).
As hypothesized, higher levels of depressive affect
significantly correlated with decreased medication adherence
in the HD sample (r¼0.47, P¼ 0.001), the transplant
sample (r¼0.38, P¼ 0.001) (Figure 1), and the combined
sample (r¼0.47, P¼ 0.001) (Table 2). In a test for
homogeneity of slopes, the differences between the two
regressions were not significantly different (P¼ 0.43).
Pertinent associations from this analysis include increased
age’s associations with fewer hospitalizations and less
medication adherence in the HD sample. In the transplant
sample, increased age was associated with having a chance
LOC. The three dimensions of LOC (internal, powerful other,
and chance) were all significantly inter-correlated, but none
were associated with either depression (P40.05) or adher-
ence (P40.05) in the transplant group.
Medication adherence
Patients were categorized to one of three groups based on
their level of adherence: Perfect Adherence (12/12 on the
ITAS-M), Nearly Perfect Adherence (10–11 on the ITAS-M),
and Less Than Perfect Adherence to the medication regimen
(9 or below on the ITAS-M). Fifty-one percent (n¼ 78) of
the entire sample reported Perfect Adherence, 30% (n¼ 46)
reported Nearly Perfect Adherence, and 19% (n¼ 29)
reported Less Than Perfect Adherence to their medication
prescription. In comparison with the HD cohort, a higher
proportion of the transplant sample reported Perfect
Adherence (w2¼ 4.939, P¼ 0.36) and a smaller proportion
reported Less Than Perfect Adherence (w2¼ 25.738,
Po0.001) (Table 1).
12
10
8
6
4
2
0
0 10 20 30 40 50 60
Depressive affect (BDI)
Transplant
Hemodialysis
Ad
he
re
nc
e 
(IT
AS
-M
)
r = –0.38
r = –0.47
Figure 1 | Adherence by depression for transplant and
hemodialysis samples.
Table 2 | Correlations for the hemodialysis, transplant, and combined samples
Age Hospital Education LOC-Internal LOC-Powerful LOC-Chance Depression (BDI)
Hemodialysis sample (n=65)
Age —
Hospital 0.37** —
Education 0.22 0.73 —
LOC-Internal 0.22 0.11 0.08 —
LOC-Powerful 0.14 0.02 0.13 0.25 —
LOC-Chance 0.072 0.08 0.22 0.12 0.43** —
Depression (BDI) 0.067 0.23 0.06 0.12 0.14 0.10 —
Adherence (ITAS-M) 0.34** 0.01 0.15 0.09 0.02 0.04 0.47**
Transplant sample (n=95)
Age —
Hospital 0.08 —
Education 0.07 0.03 —
LOC-Internal 0.03 0.16 0.10 —
LOC-Powerful 0.15 0.11 0.05 0.44** —
LOC-Chance 0.23* 0.14 0.18 0.38** 0.43** —
Depression (BDI) 0.08 0.09 0.02 0.13 0.24* 0.01 —
Adherence (ITAS-M) 0.02 0.02 0.09 0.01 0.01 0.17 0.38**
Combined sample (n=160)
Age —
Hospital 0.12 —
Education 0.14 0.05 —
LOC-Internal 0.06 0.08 0.09 —
LOC-Powerful 0.14 0.03 0.08 0.39** —
LOC-Chance 0.20* 0.14 0.19* 0.28** 0.42** —
Depression (BDI) 0.01 0.25** 0.03 0.13 0.09 0.01 —
Adherence (ITAS-M) 0.10 0.08 0.02 0.00 0.01 0.11 0.47**
Hospital, hospitalizations in last 12 months; LOC, Multidimensional Health Locus of Control Scales; BDI, Beck Depression Inventory; ITAS-M. Modified Immunosuppressive
Adherence Scale.
*Po0.05, **Po0.01.
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In the combined total sample, patients who reported
themselves to be Less Than Perfectly Adherent with their
medication regimen had significantly higher BDI scores
(M¼ 18.2, s.d.¼ 14.4), (F¼ 23.4, Po0.001) than those who
reported Perfect Adherence (M¼ 5.8, s.d.¼ 5.6) and Nearly
Perfect Adherence (M¼ 8.2, s.d.¼ 7.3). Interestingly, the
three groups did not differ significantly on the MHLOC. In
addition, individuals who were likely to be clinically
depressed (BDI X15) reported significantly less adherence
(M¼ 8.1, s.d.¼ 3.8) than did non-depressed patients
(M¼ 10.9, s.d.¼ 2.1) (t¼5.46, Po0.001).
Predictors of medication adherence
Hierarchical multiple regression analyses were used to
determine predictors of medication adherence while control-
ling for demographic and treatment variables (Table 3).
Medication adherence was the dependent variable, and
demographic information (gender, hospitalizations, educa-
tion, age, and ethnicity) and method of treatment (HD as the
referent group or TX) were entered first and psychological
variables (BDI, LOC) were entered second. The first step of
the model was significant (F¼ 4.51, Po0.001) and accounted
for 18% of the variance in medication adherence. The most
powerful demographic predictor was mode of treatment
(t¼ 4.039, Po0.001). The second step accounted for an
additional 12% of the variance in the ITAS-M total score
(F¼ 3.82, Po0.001). Depression was the only additional
statistically significant predictor of medication adherence
(t¼2.97, P¼ 0.001).
DISCUSSION
Non-adherence is a profound problem in ESRD patients,
both owing to its prevalence within the population as well as
its impact on health outcomes. This study compared ESRD
patients including both current kidney transplant patients
and patients treated with HD on psychological measures and
self-reported medication adherence.
Depression emerged as a significant predictor of medica-
tion adherence across the range of patients receiving
treatment for ESRD. This pattern of association held true
in each of the treatment samples individually (HD and TX)
and in the combined sample. In contrast with earlier
literature,34–36 the majority of the demographic variables of
our sample did not reach significance in the regression
model, with the exception of gender. In our urban, primarily
black population, we found that the traditional demographic
predictors of medication adherence explained only a
relatively small percentage of the variance in medication
adherence. The reason for this is unclear; however, it is
possible that within this specific population there is a
different relationship between demographic variables than
when this population is compared with other, more
heterogeneous samples. In addition, individuals who reached
levels of clinical depression as measured by the BDI reported
significantly less medication adherence than people who
reported only mild depressive affect. This highlights the
necessity for identifying patients who score in the clinical
range on the BDI, as these individuals are particularly at risk
for non-adherence when compared with those with sub-
clinical depression. These results argue for the routine
screening for depression in the promotion of greater
medication adherence.37
Although an objective measure such as blood chemistry
would be ideal for measuring medication adherence, there are
no available markers sensitive to fluctuations in medication
adherence5,38,39 Microelectronic monitoring methods such as
Medication Event Monitoring Systems Caps are useful for
monitoring medication adherence, yet expensive and have
their limitations.39–41 Self-report medication adherence was
chosen as it has the most desirable balance between accuracy,
ease of administration, and cost-effectiveness.
Some interesting differences between ESRD patients
treated with HD and those with a functioning kidney
transplant emerged. Those in the HD group were more
depressed than those who received a kidney transplant. These
findings are consistent with the general finding that
transplant patients have a higher health-related quality of
life when compared with HD patients (see Liem et al.36 for a
recent meta-analysis). HD patients also reported less
medication adherence compared with those in the transplant
group. Despite the lack of a universal instrument to measure
adherence, both groups reported levels of adherence roughly
consistent with other studies. Difficulty with immunosup-
pressive medication adherence in transplant patients ranges
from 2 to 26%,42 and 19% of our transplant sample reported
Less Than Perfect Adherence. Rates for non-adherence to the
dialysis prescription, including medication, fluid intake, diet
regimen, and medical appointments, range from 30–60%.5,43
Our HD sample reported 37% less than Perfect Adherence to
their medication regimen. Despite there being differences in
adherence levels between the two ESRD groups, depression
was still a significant predictor of medication adherence.
In addition to reporting higher depressive affect and
poorer adherence, our HD cohort used more of a chance
LOC. Despite an expectation that MHLOC would be
Table 3 | Multiple regression predicting ITAS-M
R F b t
Dependent variable: ITAS-M total score
Step 1 0.426 4.51**
Age 0.178 1.86
Gender 0.201 2.21*
Education 0.037 0.403
Ethnicity 0.087 0.938
Mode of treatment -
HD (referent) or TX
0.389 4.04**
Step 2 0.509 3.82**
BDI 0.287 2.97**
LOC-Internal 0.020 0.204
LOC-Powerful 0.114 1.10
LOC-Chance 0.012 0.118
BDI, Beck Depression Inventory; HD, hemodialysis; ITAS-M, Modified Immunosup-
pressive Adherence Scale; LOC, Locus of Control.
*Po0.05, **Po0.01.
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associated with depression and adherence, this was primarily
not supported. In fact, the three subscales of the MHLOC,
internal, powerful other, and chance were all highly inter-
correlated, indicating that this measure did not perform as
expected in our sample. This may be specific to our patients,
or it is possible that the MHLOC does not perform as
expected in minority ESRD populations. Although some
earlier studies with primarily non-black patients have found
LOC to be associated with adherence in ESRD,31,44 LOC did
not contribute significantly to the impact on medication
adherence in our population.
A major limitation of the study design is that it relied
exclusively on a ‘self-report’ measure for medication
adherence. We elected to use self-report over other forms
of adherence measurements as they are prohibitively
expensive and cumbersome and there is little evidence that
they are superior to self-report instruments. However, self-
reporting has been shown to overestimate true adher-
ence.39,41,44 Therefore, the current relationships may be even
stronger than reported owing to the measurement error. We
do not believe that there was a differential bias in self-
reporting between the two ESRD groups. However, it is
possible that the transplant patients who risk a lower United
Network of Organ Sharing (UNOS) ranking owing to non-
adherence might be more likely to erroneously report Perfect
Adherence than HD patients.
Another possible limitation of this study is that it
specifically assessed medication adherence by using the same
measure of adherence in both samples. Although medication
adherence is an important aspect of both transplant and HD,
this study did not examine the impact of depression on other
types of adherence, such as dietary or behavioral compliance
with the transplant or dialysis prescription.5
Our sample is not representative of the USRDS as our
community and patients are predominantly Black, a minority
group that has the highest incidence and prevalence rates of
ESRD.45 There has even been the suggestion of poorer
adherence by minority patients in both organ transplant
populations13 and HD patients.46 As health disparities
between blacks and whites have been well documented in
ESRD, with an overrepresentation of blacks in the US dialysis
population1 and an underrepresentation in the transplant
population,47 understanding this understudied population is
paramount.
The findings of this study have important implications for
the identification of factors that are associated with
compromised adherence in ESRD populations. Depression
is ubiquitous in ESRD and in this study accounted for 24% of
the variance beyond traditional demographic factors in
adherence. Depression has been shown to be treated
effectively in ESRD populations.48,49 Treating depression, in
addition to providing improvement in the quality of life,
should also be an essential component of any intervention
designed to promote medication adherence in patients on
dialysis and should continue after a successful kidney
transplant. The time to routinely screen for and treat
depression in ESRD samples has truly arrived, and now
there is a further suggestion that treating depression could
have a major positive impact on patient adherence.
MATERIALS AND METHODS
Participants
Participants were recruited from the transplant clinic and dialysis
center of Downstate Medical Center in Brooklyn, New York.
Consecutive transplant patients waiting for their monthly medical
appointment were approached in the waiting room of the transplant
clinic until the desired sample size was achieved. All dialysis patients
were approached while receiving HD. Patients who expressed an
interest in participating were informed about the study and then
provided informed consent. Participants were given a packet of
paper and pencil questionnaires regarding their current psycho-
logical functioning and other demographic information. One
hundred fifty-four transplant patients were approached; 98 agreed
to complete the self-report standardized instruments with informed
consent. Four subjects did not complete all of the questionnaires
and were therefore excluded. Eighty-nine dialysis patients were
approached, and 65 completed the measures with informed consent.
Measures
Beck Depression Inventory-II. The BDI is a 21-item self-report
instrument with high scores (range¼ 0–63) reflecting the presence
and severity of depressed mood. It is a reliable and well-validated
measure of depressive symptomatology in both clinical and
nonclinical samples.50 The BDI has been used extensively in
ESRD populations.18,21,48,49 The standard cutoff for depression
is a score of 10 or greater in the general population;50 however,
in ESRD populations, a score of 15 or greater has been
suggested.18,19,21,23,51,52
Medication Therapy Adherence Scale. The ITAS-M is a
modified version of the Immunosuppressive Adherence Scale,53
which is a short questionnaire designed to be a valid and reliable
instrument that measures patients’ self-reported adherence to
immunosuppressive medication. The ITAS-M assesses how often
individuals forget to take their medication as well as their
carelessness with taking their medication in the past 3 months.
There are four questions measuring adherence, each scored by
percentages of non-adherence (450% of the time, 21–50% of the
time, 1–20% of the time, and 0% of the time). The total score reflects
the sum of the four individual items, with a higher score being
indicative of greater adherence. The ITAS has been shown to have
acceptable reliability and validity in organ donation.53 The only
modification we used was to expand the phrasing to refer to all
medications, not simply immunosuppressive medications.
Multidimensional Health LOC Scales (MHLOC). The MHLOC
is an 18-item, self-report measure designed to describe a person’s belief
about where the control over health lies.54 The items are answered on a
6-point Likert scale ranging from ‘strongly agree’ to ‘strongly disagree.’
The MHLOC scale produces three scores: Internal (LOC-Internal),
Powerful Other (LOC- Powerful Other), and Chance (LOC-Chance).
It is a well-validated and reliable instrument that has been used
extensively in chronic illness literature,55 ESRD patients treated with
HD,29,30 and transplant literature.56
Statistical analyses
All data were analyzed using the computer-based statistical software
package SPSS (version 14.0). Descriptive statistics were calculated
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for the sample population and the subgroups. Group differences for
continuous variables were compared with t-tests and with the w2 for
non-continuous variables. Pearson’s correlations were derived, and
tests of significance were set at 0.05. A t-test was used to compare the
difference between the depression-adherence correlation in each of
the treatment subgroups. Finally, for identification of the unique
variance in self-reported medication adherence as a result of
depressive affect once the common variance of demographic and
treatment variables were controlled, a hierarchical multiple regres-
sion was used. Age, gender, education, ethnicity, and mode of
treatment were entered first, and depression and LOC variables were
entered as the second step.
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